DekaBank Deutsche Girozentrale lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 15.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,152 shares of the biotechnology company’s stock after purchasing an additional 28,408 shares during the period. DekaBank Deutsche Girozentrale owned 0.10% of Biogen worth $64,011,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. Guardian Life Insurance Co. of America lifted its holdings in shares of Biogen by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 6 shares during the period. Carroll Financial Associates Inc. lifted its holdings in Biogen by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 6 shares during the period. RMB Capital Management LLC lifted its holdings in Biogen by 1.1% in the first quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 9 shares during the period. New Amsterdam Partners LLC NY lifted its holdings in Biogen by 0.8% in the second quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 11 shares during the period. Finally, Alta Capital Management LLC lifted its holdings in Biogen by 0.8% in the second quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock valued at $510,000 after buying an additional 15 shares during the period. Institutional investors own 88.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-acquires-28408-shares-of-biogen-inc-biib/1702924.html.

Several research firms recently issued reports on BIIB. UBS AG restated a “neutral” rating and issued a $285.00 target price (up previously from $270.00) on shares of Biogen in a report on Wednesday, July 26th. Mizuho set a $400.00 target price on shares of Biogen and gave the company a “buy” rating in a report on Monday. Goldman Sachs Group, Inc. (The) upgraded shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price on the stock in a report on Wednesday, August 16th. Vetr lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $316.82 target price on the stock. in a report on Monday, September 4th. Finally, Morgan Stanley upgraded shares of Biogen from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $311.00 to $375.00 in a report on Thursday, October 5th. Twelve research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $341.89.

Biogen Inc. (BIIB) traded up $5.27 on Tuesday, reaching $315.71. 1,186,700 shares of the company’s stock were exchanged, compared to its average volume of 1,518,202. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $66,770.00, a PE ratio of 14.38, a price-to-earnings-growth ratio of 1.94 and a beta of 0.72. Biogen Inc. has a 52-week low of $244.28 and a 52-week high of $348.84.

Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $5.19 earnings per share. sell-side analysts expect that Biogen Inc. will post 22.03 EPS for the current year.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.